-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Db7LneojsAbx6hUSWq8MagvyQzwL9URRxVBNUpZWSXwZ+iY9kzRvg3Ovq8TIeSLI
 G5rPiEyGppYv6hSplpR5IA==

<SEC-DOCUMENT>0001102624-06-000192.txt : 20060721
<SEC-HEADER>0001102624-06-000192.hdr.sgml : 20060721
<ACCEPTANCE-DATETIME>20060721102629
ACCESSION NUMBER:		0001102624-06-000192
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060720
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20060721
DATE AS OF CHANGE:		20060721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		06973158

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934.
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: July      20, 2006</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 width="40%" valign="top">
<b>DE</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>001-12934</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 width="40%" valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive, Portland, Maine</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>(207) 878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On July 20, 2006 ImmuCell Corporation (the "Company") issued a press release announcing its financial results for the three and six month periods ended June 30, 2006.  The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.  The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act ("the Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br>
<br><b>(a) Financial statements:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(b) Pro forma financial information:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(c) Shell company transactions:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(d) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated July      20, 2006</a></b>
<p>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table>
<tr>
<td width="50%" valign=top>
Dated: July      21, 2006<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President and CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated July      20, 2006</td>
</tr>
</table>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Financial Results for Second Quarter and First Half of 2006</b>
<p>PORTLAND, ME -- 07/20/2006 --  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three and six month periods
ended June 30, 2006.
</p>
<p>
For the three months ended June 30, 2006, product sales decreased by 12%,
or $99,000, to $749,000, in comparison to the same period in 2005.  For the
six months ended June 30, 2006, product sales decreased by 4%, or $89,000,
to $2,187,000, in comparison to the same period in 2005.
</p>
<p>
"Sales of First Defense&#174;, our lead product, increased by 3% and 4% during
the three and six month periods ended June 30, 2006, respectively,"
commented Michael F. Brigham, president and CEO.  "Continued growth of
First Defense&#174; is the key to our commercial strategy while Mast Out&#174; is
being developed under a product development and marketing agreement with
Pfizer Animal Health."
</p>
<p>
Net income was $0.11 per diluted share in both of the six month periods
ended June 30, 2006 and 2005. The Company recognized net income of $16,000
for the three months ended June 30, 2006, compared to net income of $79,000
during the same period in 2005.  For the six months ended June 30, 2006,
the Company recognized net income of $322,000, compared to net income of
$339,000 during the same period in 2005.
</p>
<p>
The Company's cash, cash equivalents and short-term investments increased
by 15%, or $770,000, to $5,920,000 at June 30, 2006, as compared to
$5,150,000 at December 31, 2005.  Stockholders' equity increased by 6%, or
$509,000, to $9,066,000 at June 30, 2006, as compared to $8,558,000 at
December 31, 2005.  The Company had 2,909,000 shares of common stock
outstanding as of June 30, 2006.
</p>
<p>
<br>
<pre>
                                        (Unaudited)        (Unaudited)
                                    Three Months Ended  Six Months Ended
                                          June 30,           June 30,
                                       2006     2005      2006     2005
(In thousands, except per share      -------  -------   -------  -------
 amounts)
Revenues:
Product sales                        $   749  $   848   $ 2,187  $ 2,276
Other revenues                            93      136       198      304
                                     -------  -------   -------  -------
Total revenues                           842      984     2,385    2,580

Cost and expenses:
Product costs                            386      349       895      911
Research and development expenses        231      253       466      567
Selling, general and administrative
 expenses                                257      278       599      585
                                     -------  -------   -------  -------
Total costs and expenses                 874      880     1,960    2,063
                                     -------  -------   -------  -------

Net operating (loss) income              (32)     104       425      517

Interest and other income                 64       31       116       53
                                     -------  -------   -------  -------

Income before income taxes                32      135       541      570
Income tax expense                        16       56       219      231
                                     -------  -------   -------  -------
Net income                           $    16  $    79   $   322  $   339
                                     =======  =======   =======  =======

Net income per common share:
Basic                                $  0.01  $  0.03   $  0.11  $  0.12
Diluted                              $  0.01  $  0.03   $  0.11  $  0.11

Weighted average common shares
 outstanding:
Basic                                  2,893    2,804     2,872    2,799
Diluted                                3,073    2,956     3,055    2,976




                                                            (Unaudited)
                                 At December 31, 2005    At June 30, 2006
                                 --------------------  --------------------
(In thousands)
Cash, cash equivalents and
 short-term investments                  $5,150                $5,920
Total assets                              9,955                10,222
Net working capital                       6,091                 6,707
Stockholders' equity                     $8,558                $9,066
</pre>
</p>
<p>
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries.  Press releases and other
information about the Company are available at http://www.immucell.com.

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
